OMEGAVEN (fatty acids combo. no.6/fish oil/glycerin)
LIPIDS·TPN-ASSOCIATED CHOLESTASIS
FRESENIUS KABI
Indication
TPN-associated Cholestasis
TPN-associated cholestasis is an iatrogenic hepatobiliary complication characterized by impaired bile formation and secretion resulting from prolonged total parenteral nutrition. Read more about TPN-associated Cholestasis
1 drugs 1 manufacturers
Drugs that treat it
Common TPN-associated Cholestasis therapies.
Filter & compare in the drug finder →Opens the drug finder with TPN-associated Cholestasis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonTPN-associated cholestasis is an iatrogenic hepatobiliary complication characterized by impaired bile formation and secretion resulting from prolonged total parenteral nutrition.
It most commonly affects premature infants and neonates with gastrointestinal failure, though it can also occur in children and adults on extended intravenous nutritional support.
Pathophysiologically, the condition is driven by multifactorial mechanisms, including the absence of enteral stimulation, disruption of enterohepatic bile circulation, and intravenous lipid or phytosterol toxicity.
Clinically, it is defined by conjugated hyperbilirubinemia, elevated serum alkaline phosphatase, and progressive histological features that may advance from portal inflammation and intracanalicular cholestasis to hepatic fibrosis and cirrhosis.
- nih.gov
TPN-associated cholestasis is an iatrogenic hepatobiliary complication characterized by impaired bile formation and secretion resulting from prolonged total parenteral nutrition Clinically, it is defined by conjugated hyperbilirubinemia, elevated serum alkaline phosphatase, and progressive histological features that may advance from portal inflammation and intracanalicular cholestasis to hepatic fibrosis and cirrhosis
- nih.gov
TPN-associated cholestasis is an iatrogenic hepatobiliary complication characterized by impaired bile formation and secretion resulting from prolonged total parenteral nutrition It most commonly affects premature infants and neonates with gastrointestinal failure, though it can also occur in children and adults on extended intravenous nutritional support Clinically, it is defined by conjugated hyperbilirubinemia, elevated serum alkaline phosphatase, and progressive histological features that may...
- nih.gov
It most commonly affects premature infants and neonates with gastrointestinal failure, though it can also occur in children and adults on extended intravenous nutritional support
- riteaid.com
It most commonly affects premature infants and neonates with gastrointestinal failure, though it can also occur in children and adults on extended intravenous nutritional support
- nih.gov
Pathophysiologically, the condition is driven by multifactorial mechanisms, including the absence of enteral stimulation, disruption of enterohepatic bile circulation, and intravenous lipid or phytosterol toxicity
- nih.gov
Pathophysiologically, the condition is driven by multifactorial mechanisms, including the absence of enteral stimulation, disruption of enterohepatic bile circulation, and intravenous lipid or phytosterol toxicity
- nih.gov
Clinically, it is defined by conjugated hyperbilirubinemia, elevated serum alkaline phosphatase, and progressive histological features that may advance from portal inflammation and intracanalicular cholestasis to hepatic fibrosis and cirrhosis
Personalize your experience
Follow TPN-associated Cholestasis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.